JP2023009229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023009229A5 JP2023009229A5 JP2022183229A JP2022183229A JP2023009229A5 JP 2023009229 A5 JP2023009229 A5 JP 2023009229A5 JP 2022183229 A JP2022183229 A JP 2022183229A JP 2022183229 A JP2022183229 A JP 2022183229A JP 2023009229 A5 JP2023009229 A5 JP 2023009229A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dose
- imetelstat
- weeks
- intravenous administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940075628 hypomethylating agent Drugs 0.000 claims 8
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical group N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 claims 7
- 229950004291 imetelstat Drugs 0.000 claims 7
- 238000001990 intravenous administration Methods 0.000 claims 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- 229960004942 lenalidomide Drugs 0.000 claims 3
- 229940123582 Telomerase inhibitor Drugs 0.000 claims 2
- 239000003173 antianemic agent Substances 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims 2
- IEVORMRANFJJFR-NMZIRJKDSA-A imetelstat sodium Chemical group [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@@H]2O[C@@H]([C@H](C2)NP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O IEVORMRANFJJFR-NMZIRJKDSA-A 0.000 claims 2
- 239000003277 telomerase inhibitor Substances 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023197448A JP7654761B2 (ja) | 2017-07-28 | 2023-11-21 | 骨髄異形成症候群の治療方法 |
| JP2024197684A JP2025013669A (ja) | 2017-07-28 | 2024-11-12 | 骨髄異形成症候群の治療方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538315P | 2017-07-28 | 2017-07-28 | |
| US62/538,315 | 2017-07-28 | ||
| US201762595329P | 2017-12-06 | 2017-12-06 | |
| US62/595,329 | 2017-12-06 | ||
| US201862685542P | 2018-06-15 | 2018-06-15 | |
| US62/685,542 | 2018-06-15 | ||
| PCT/US2018/044225 WO2019023667A1 (en) | 2017-07-28 | 2018-07-27 | METHODS OF TREATING MYELODYSPLASTIC SYNDROME |
| JP2020504178A JP7316261B2 (ja) | 2017-07-28 | 2018-07-27 | 骨髄異形成症候群の治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504178A Division JP7316261B2 (ja) | 2017-07-28 | 2018-07-27 | 骨髄異形成症候群の治療方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197448A Division JP7654761B2 (ja) | 2017-07-28 | 2023-11-21 | 骨髄異形成症候群の治療方法 |
| JP2024197684A Division JP2025013669A (ja) | 2017-07-28 | 2024-11-12 | 骨髄異形成症候群の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023009229A JP2023009229A (ja) | 2023-01-19 |
| JP2023009229A5 true JP2023009229A5 (enExample) | 2023-05-26 |
| JP7654615B2 JP7654615B2 (ja) | 2025-04-01 |
Family
ID=63209674
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504178A Active JP7316261B2 (ja) | 2017-07-28 | 2018-07-27 | 骨髄異形成症候群の治療方法 |
| JP2022183229A Active JP7654615B2 (ja) | 2017-07-28 | 2022-11-16 | 骨髄異形成症候群の治療方法 |
| JP2023197448A Active JP7654761B2 (ja) | 2017-07-28 | 2023-11-21 | 骨髄異形成症候群の治療方法 |
| JP2024197684A Pending JP2025013669A (ja) | 2017-07-28 | 2024-11-12 | 骨髄異形成症候群の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504178A Active JP7316261B2 (ja) | 2017-07-28 | 2018-07-27 | 骨髄異形成症候群の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197448A Active JP7654761B2 (ja) | 2017-07-28 | 2023-11-21 | 骨髄異形成症候群の治療方法 |
| JP2024197684A Pending JP2025013669A (ja) | 2017-07-28 | 2024-11-12 | 骨髄異形成症候群の治療方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12171778B2 (enExample) |
| EP (2) | EP3658156B1 (enExample) |
| JP (4) | JP7316261B2 (enExample) |
| KR (2) | KR102867725B1 (enExample) |
| CN (2) | CN110944646A (enExample) |
| AU (2) | AU2018307983B2 (enExample) |
| BR (1) | BR112020001749A2 (enExample) |
| CA (1) | CA3069010A1 (enExample) |
| CL (2) | CL2020000196A1 (enExample) |
| DK (1) | DK3658156T3 (enExample) |
| ES (1) | ES3073105T3 (enExample) |
| FI (1) | FI3658156T3 (enExample) |
| HR (1) | HRP20260793T1 (enExample) |
| IL (2) | IL324714A (enExample) |
| LT (1) | LT3658156T (enExample) |
| MA (1) | MA49688B1 (enExample) |
| MD (1) | MD3658156T2 (enExample) |
| MX (1) | MX2025005894A (enExample) |
| NZ (2) | NZ802277A (enExample) |
| PL (1) | PL3658156T3 (enExample) |
| PT (1) | PT3658156T (enExample) |
| RS (1) | RS68210B1 (enExample) |
| SG (1) | SG11201913984RA (enExample) |
| SI (1) | SI3658156T1 (enExample) |
| SM (1) | SMT202600247T1 (enExample) |
| TW (2) | TWI906757B (enExample) |
| UA (1) | UA127701C2 (enExample) |
| WO (1) | WO2019023667A1 (enExample) |
| ZA (1) | ZA202000070B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| EP3658156B1 (en) | 2017-07-28 | 2026-03-25 | Geron Corporation | Telomerase inhibitor for use in treating a myelodysplastic syndrome |
| CN113631719A (zh) * | 2018-11-29 | 2021-11-09 | 美国杰龙生物医药公司 | 治疗骨髓增生异常综合征的方法 |
| CA3181682A1 (en) | 2020-07-17 | 2022-01-20 | Anil Kapur | Subcutaneous telomerase inhibitor compositions and methods for using same |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| HK1049339B (en) | 1999-09-10 | 2008-06-27 | Geron Corporation | Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use |
| AU2001227965A1 (en) | 2000-01-21 | 2001-07-31 | Geron Corporation | 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
| DK3342425T3 (da) | 2003-09-09 | 2020-03-16 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
| DE602004031975D1 (de) | 2003-11-04 | 2011-05-05 | Geron Corp | Rna-amidate und thioamidateur rnai |
| US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
| RS61840B1 (sr) | 2004-07-02 | 2021-06-30 | Geron Corp | Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera |
| FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US20060166221A1 (en) | 2005-01-21 | 2006-07-27 | Bahou Wadie F | Methods of diagnosing essential thrombocythemia |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2006113426A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and tubulin activities |
| TW200730485A (en) | 2005-07-29 | 2007-08-16 | Kalypsys Inc | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| US20070224598A1 (en) | 2006-03-15 | 2007-09-27 | The Methodist Hospital Research Institute | System and method for detection of mutations in JAK2 polynucleotides |
| WO2007127163A2 (en) | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| EP4600359A2 (en) | 2006-10-30 | 2025-08-13 | Geron Corporation | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
| WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| ES2407957T3 (es) | 2007-03-09 | 2013-06-17 | Geron Corporation | Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa |
| US8367078B2 (en) | 2007-06-06 | 2013-02-05 | University Of Florida Research Foundation, Inc. | Kinase inhibitor compounds |
| CN101220044B (zh) | 2008-01-21 | 2010-06-02 | 中国药科大学 | 端粒酶抑制剂及其制备方法和用途 |
| US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
| EP2304436A1 (en) | 2008-07-10 | 2011-04-06 | Nodality, Inc. | Methods for diagnosis, prognosis and treatment |
| EP3719139B1 (en) | 2008-10-17 | 2022-11-30 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
| US8772264B2 (en) | 2009-08-04 | 2014-07-08 | Mayo Foundation For Medical Education And Research | Methods of treating hematologic cancers |
| ES2616055T3 (es) | 2010-02-12 | 2017-06-09 | Qiagen Marseille | ASXL1 como nuevo marcador de diagnóstico de neoplasias mieloides |
| WO2012149339A2 (en) | 2011-04-29 | 2012-11-01 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
| US20150005250A1 (en) | 2011-10-13 | 2015-01-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome |
| US20140303191A1 (en) | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2857490C (en) | 2011-12-22 | 2020-03-31 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| LT2925889T (lt) | 2012-11-30 | 2018-12-27 | Geron Corporation | Diagnostiniai žymenys, skirti ląstelių prolifreracijos sutrikimų gydymui telomerazės inhibitoriais |
| PT3456333T (pt) | 2012-12-07 | 2020-06-01 | Geron Corp | Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica |
| US9375485B2 (en) * | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US20150342982A1 (en) * | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
| WO2014160071A1 (en) | 2013-03-14 | 2014-10-02 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| US11123359B2 (en) | 2013-11-06 | 2021-09-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating hematological malignancies |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| EP3658156B1 (en) | 2017-07-28 | 2026-03-25 | Geron Corporation | Telomerase inhibitor for use in treating a myelodysplastic syndrome |
-
2018
- 2018-07-27 EP EP18755608.9A patent/EP3658156B1/en active Active
- 2018-07-27 KR KR1020207003450A patent/KR102867725B1/ko active Active
- 2018-07-27 AU AU2018307983A patent/AU2018307983B2/en active Active
- 2018-07-27 FI FIEP18755608.9T patent/FI3658156T3/fi active
- 2018-07-27 CA CA3069010A patent/CA3069010A1/en active Pending
- 2018-07-27 TW TW113103931A patent/TWI906757B/zh active
- 2018-07-27 LT LTEPPCT/US2018/044225T patent/LT3658156T/lt unknown
- 2018-07-27 PL PL18755608.9T patent/PL3658156T3/pl unknown
- 2018-07-27 SI SI201831321T patent/SI3658156T1/sl unknown
- 2018-07-27 TW TW107126009A patent/TWI879717B/zh active
- 2018-07-27 IL IL324714A patent/IL324714A/en unknown
- 2018-07-27 JP JP2020504178A patent/JP7316261B2/ja active Active
- 2018-07-27 NZ NZ802277A patent/NZ802277A/en unknown
- 2018-07-27 MD MDE20200587T patent/MD3658156T2/ro unknown
- 2018-07-27 HR HRP20260793TT patent/HRP20260793T1/hr unknown
- 2018-07-27 EP EP26159006.1A patent/EP4763279A3/en active Pending
- 2018-07-27 WO PCT/US2018/044225 patent/WO2019023667A1/en not_active Ceased
- 2018-07-27 UA UAA202000156A patent/UA127701C2/uk unknown
- 2018-07-27 DK DK18755608.9T patent/DK3658156T3/da active
- 2018-07-27 PT PT187556089T patent/PT3658156T/pt unknown
- 2018-07-27 US US16/047,502 patent/US12171778B2/en active Active
- 2018-07-27 RS RS20260721A patent/RS68210B1/en unknown
- 2018-07-27 SM SM20260247T patent/SMT202600247T1/it unknown
- 2018-07-27 NZ NZ802272A patent/NZ802272A/en unknown
- 2018-07-27 BR BR112020001749-3A patent/BR112020001749A2/pt not_active Application Discontinuation
- 2018-07-27 CN CN201880049391.2A patent/CN110944646A/zh active Pending
- 2018-07-27 ES ES18755608T patent/ES3073105T3/es active Active
- 2018-07-27 SG SG11201913984RA patent/SG11201913984RA/en unknown
- 2018-07-27 MA MA49688A patent/MA49688B1/fr unknown
- 2018-07-27 CN CN202511334144.5A patent/CN121243203A/zh active Pending
- 2018-07-27 KR KR1020257032602A patent/KR20250151565A/ko active Pending
-
2020
- 2020-01-06 ZA ZA2020/00070A patent/ZA202000070B/en unknown
- 2020-01-21 IL IL272163A patent/IL272163B1/en unknown
- 2020-01-23 CL CL2020000196A patent/CL2020000196A1/es unknown
- 2020-01-24 MX MX2025005894A patent/MX2025005894A/es unknown
-
2021
- 2021-04-28 CL CL2021001096A patent/CL2021001096A1/es unknown
-
2022
- 2022-11-16 JP JP2022183229A patent/JP7654615B2/ja active Active
-
2023
- 2023-11-21 JP JP2023197448A patent/JP7654761B2/ja active Active
-
2024
- 2024-09-20 AU AU2024219941A patent/AU2024219941B2/en active Active
- 2024-11-06 US US18/938,747 patent/US20260115223A1/en active Pending
- 2024-11-12 JP JP2024197684A patent/JP2025013669A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272410B2 (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| IL272300B2 (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| IL272274B2 (en) | Antibodies 4h-7b Methods of using them | |
| IL272163B1 (en) | Imetelstat for use in treating myelodysplastic syndrome | |
| JP2020528915A5 (enExample) | ||
| RU2003131876A (ru) | Композиции n-ацетилцистеина и способы лечения и профилактики токсичности лекарственных средств | |
| JP2022527359A5 (enExample) | ||
| JP2020509024A5 (enExample) | ||
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| JP2024516363A5 (enExample) | ||
| KR101174966B1 (ko) | 철이 발병에 관여하는 간질환의 치료 | |
| JP2013518124A5 (enExample) | ||
| JP2017533972A5 (enExample) | ||
| JP2021512906A5 (enExample) | ||
| JP2022529312A5 (enExample) | ||
| CN102083435A (zh) | 特拉匹韦给药方案 | |
| JP2025148449A5 (enExample) | ||
| JP2022551691A5 (enExample) | ||
| JP2023531930A5 (enExample) | ||
| JP2012533542A5 (enExample) | ||
| EA024723B1 (ru) | Применение лекарственной формы хлорида аммония для профилактики или лечения вирусной инфекции и состояний, вызванных токсическими веществами | |
| JP2024525164A5 (enExample) | ||
| JP2024531799A5 (enExample) | ||
| CA2535451A1 (en) | Method of treating viral infections | |
| JP2017502058A5 (enExample) |